Trials / Suspended
SuspendedNCT04860635
Safety of F14 Following Total Knee Replacement
An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement
- Status
- Suspended
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Arthritis Innovation Corporation · Industry
- Sex
- All
- Age
- 45 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and multimodal analgesia
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | F14 (sustained release celecoxib) | Celecoxib in BEPO® drug delivery system |
Timeline
- Start date
- 2026-09-01
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
- First posted
- 2021-04-27
- Last updated
- 2025-11-26
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04860635. Inclusion in this directory is not an endorsement.